- Home
- ANGO vs IMMP Comparison
ANGO vs IMMP Comparison
Compare ANGO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | IMMP |
|---|---|---|
| Founded | 1988 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.2M | 426.9M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANGO | IMMP |
|---|---|---|
| Price | $10.05 | $2.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.33 | N/A |
| AVG Volume (30 Days) | ★ 618.3K | 465.4K |
| Earning Date | 01-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,306,000.00 | $3,306,742.00 |
| Revenue This Year | $8.18 | $292.48 |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.26 | ★ 31.28 |
| 52 Week Low | $8.27 | $1.32 |
| 52 Week High | $13.99 | $3.53 |
Technical Indicators
Market Signals| Indicator | ANGO | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 25.07 | 65.76 |
| Support Level | $12.44 | $2.80 |
| Resistance Level | $13.37 | $3.07 |
| Average True Range (ATR) | 0.61 | 0.18 |
| MACD | -0.36 | -0.01 |
| Stochastic Oscillator | 1.28 | 60.07 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.